WASHINGTON UNIVERSITY Patent applications |
Patent application number | Title | Published |
20160000590 | Intravascular Device - An electronic intravascular device is placed in tight contact with vessel walls and is used for electrical stimulation and/or electrical recording of the vessel wall and surrounding target tissue. The electrodes may operate via connectors interfacing them to external hardware or may incorporate electronics to allow wireless power, information transfer, and control. The device includes an internal skeleton, a flexible substrate attached to the exterior of the skeleton, at least one pair of electrodes located on the substrate, and power and control circuitry connected to the electrodes. The power and control circuitry may include connectors for direct powering of the electrodes or circuit elements for wireless powering of the device by RF-based, optical-based, ultrasound-based, piezoelectric, or vibrational energy harvesting methods. The power and control circuitry may include circuit elements for wireless communication, including between the device and the external environment, and may include on-board processing for control of the electrodes. | 01-07-2016 |
20150315230 | NEUROACTIVE 19-ALKOXY-17-SUBSTITUTED STEROIDS, PRODRUGS THEREOF, AND METHODS OF TREATMENT USING SAME - The present disclosure is generally directed to neuroactive 19-alkoxy-17-substituted steroids as referenced herein, and pharmaceutically acceptable salts thereof, for use as, for example, an anesthetic, and/or in the treatment of disorders relating to GABA function and activity. The present disclosure is further directed to pharmaceutical compositions comprising such compounds. | 11-05-2015 |
20150291935 | RECOMBINANT ADENOVIRUSES AND USE THEREOF - The present invention relates to recombinant adenoviruses and vectors thereof. In particular, the adenoviruses are novel simian adenoviruses having a low seroprevalence and high immunogenicity relative to other adenoviruses and vectors thereof. The invention also provides methods for production of the adenoviruses and for the treatment of diseases by administering the adenoviral vector(s) to a subject (e.g., a human). | 10-15-2015 |
20150283209 | ACTIVIN-ACTRII ANTAGONISTS AND USES FOR TREATING BONE AND OTHER DISORDERS - Provided herein are methods for the treatment of bone disorders that are associated with kidney disease wherein the methods comprise administration of Activin-ActRIIA inhibitors to a subject in need of the treatment. Also provided herein are methods and compositions for the treatment of low turnover bone disorders wherein the methods comprise administration of Activin-ActRIIA inhibitors to a subject in need of the treatment. Further provided herein are compositions for the treatment of bone disorders that are associated with kidney disease and compositions for the treatment of low turnover bone disorders and vascular calcification. | 10-08-2015 |
20150273088 | ZAPRINAST ANALOGUES AS GLUTAMINASE INHIBITORS AND METHODS TO PREDICT RESPONSE THERETO - Zaprinast has been discovered to have activity against glutaminase 1, an important metabolic enzyme in selected cancers, for example, glutamine-dependent cancer types. Thus, glutamine-dependent cancer types, such as IDH1/2 gain-of-function mutant cancers or GLI1 overexpressing cancers, may be particularly sensitive to Zaprinast analogues. | 10-01-2015 |
20150209452 | METAL-BINDING BIFUNCTIONAL COMPOUNDS AS DIAGNOSTIC AGENTS FOR ALZHEIMER'S DISEASE - Metal-binding bifunctional compounds and their use as diagnostic agents for Alzheimer's disease and other beta amyloid disorders are disclosed. Also, radiolabeled metal complexes of these bifunctional compounds and their use as positron emission tomography (PET) imaging agents are provided. | 07-30-2015 |
20150160204 | METHODS OF POLYPEPTIDE IDENTIFICATION, AND COMPOSITIONS THEREFOR - Methods are disclosed for identifying one or more proteins or polypeptides comprised by a sample. The methods comprise determining binding of each polypeptide with respect to each binding pool of a plurality of binding pools, wherein each binding pool comprises one or more probes which bind a structure comprised by a protein or polypeptide. In some aspects, polypeptides can be denatured and separated into individual polypeptide strands and immobilized on a solid support prior to determining binding of the binding pools. A protein, polypeptide or polypeptide strand can be identified by searching, in at least one database, for a protein or polypeptide sequence comprising binding pool targets either identical to or most similar to the binding pool targets comprised by the protein, polypeptide or polypeptide strand to be identified. Kits for identifying proteins, polypeptides and polypeptide strands are also disclosed. | 06-11-2015 |
20150151268 | MICROREACTOR AND METHOD FOR PREPARING A RADIOLABELED COMPLEX OR A BIOMOLECULE CONJUGATE - A microreactor for preparing a radiolabeled complex or a biomolecule conjugate comprises a microchannel for fluid flow, where the microchannel comprises a mixing portion comprising one or more passive mixing elements, and a reservoir for incubating a mixed fluid. The reservoir is in fluid communication with the microchannel and is disposed downstream of the mixing portion. A method of preparing a radiolabeled complex includes flowing a radiometal solution comprising a metallic radionuclide through a downstream mixing portion of a microchannel, where the downstream mixing portion includes one or more passive mixing elements, and flowing a ligand solution comprising a bifunctional chelator through the downstream mixing portion. The ligand solution and the radiometal solution are passively mixed while in the downstream mixing portion to initiate a chelation reaction between the metallic radionuclide and the bifunctional chelator. The chelation reaction is completed to form a radiolabeled complex. | 06-04-2015 |
20150038560 | METHODS AND COMPOSITIONS FOR TREATING NEUROPATHIES - Methods of treating or preventing axonal degradation in neuropathic diseases in mammals are disclosed. The methods can comprise administering to the mammal an effective amount of an agent that acts by increasing sirtuin activity in diseased and/or injured neurons. The methods can also comprise administering to the mammal an effective amount of an agent that acts by increasing NAD activity in diseased and/or injured neurons. Also disclosed are methods of screening agents for treating a neuropathies and recombinant vectors for treating or preventing neuropathies. | 02-05-2015 |
20150017195 | PORCINE KNOB XENOTYPE CHIMERIC ADENOVIRAL VECTOR FOR DENDRITIC CELL INFECTION - Disclosed are methods of transforming dendritic cells with a chimeric adenovirus-5 (Ad5). A chimeric adenovirus includes a fiber comprising a tail, a shaft and a knob, wherein the knob is a porcine knob, and a nucleic acid comprising a promoter operably linked to a heterologous sequence encoding an antigen peptide. | 01-15-2015 |
20150013300 | METHOD AND APPARATUS FOR CAPTURING CARBON DIOXIDE DURING COMBUSTION OF CARBON CONTAINING FUEL - A boiler system having a series of boilers. Each boiler includes a shell having an upstream end, a downstream end, and a hollow interior. The boilers also have an oxidizer inlet entering the hollow interior adjacent the upstream end of the shell and a fuel nozzle positioned adjacent the upstream end of the shell for introducing fuel into the hollow interior of the shell. Each boiler includes a flue duct connected to the shell adjacent the downstream end for transporting flue gas from the hollow interior. Oxygen is delivered to the oxidizer inlet of the first boiler in the series. Flue gas from the immediately preceding boiler in the series is delivered through the oxidizer inlet of each boiler subsequent to the first boiler in the series. | 01-15-2015 |
20140377319 | ALTERING PROTEIN CONCENTRATIONS IN CEREBROSPINAL FLUID AND/OR BRAIN INTERSTITIAL FLUID - Devices and methods of altering protein concentrations in cerebrospinal fluid and/or brain interstitial fluid are disclosed. Devices include a support having at least one protease attached to the support. The device may further include a housing. Devices may be implantable for use in an in vivo active flow system or for use in an in vivo passive system. Devices may also be used in an ex vivo active flow system. Devices may also be used in a passive system to treat cerebrospinal fluid and/or brain interstitial fluid that is withdrawn, or in a passive system that is implanted surgically. Methods include contacting cerebrospinal fluid and/or brain interstitial fluid with a support including at least one protease attached to the support. Proteins contained in the cerebrospinal fluid and/or brain interstitial fluid are cleaved by the protease resulting in the reduction of protein in cerebrospinal fluid and/or brain interstitial fluid. Additionally, methods are disclosed for treating neurodegenerative diseases and neurological disorders. | 12-25-2014 |
20140371804 | METHOD FOR LOW-VOLTAGE TERMINATION OF CARDIAC ARRHYTHMIAS BY EFFECTIVELY UNPINNING ANATOMICAL REENTRIES - A method for extinguishing a cardiac arrhythmia utilizes destructive interference of the passing of the reentry wave tip of an anatomical reentry through a depolarized region created by a relatively low voltage electric field in such a way as to effectively unpin the anatomical reentry. Preferably, the relatively low voltage electric field is defined by at least one unpinning shock(s) that are lower than an expected lower limit of vulnerability as established, for example, by a defibrillation threshold test. By understanding the physics of the electric field distribution between cardiac cells, the method permits the delivery of an electric field sufficient to unpin the core of the anatomical reentry, whether the precise or estimated location of the reentry is known or unknown and without the risk of inducting ventricular fibrillation. A number of embodiments for performing the method are disclosed. | 12-18-2014 |
20140356282 | 100Mo compounds as accelerator targets for production of 99mTc - Methods of synthesizing | 12-04-2014 |
20140343260 | PET/SPECT AGENTS FOR APPLICATIONS IN BIOMEDICAL IMAGING - Tracers that can be used for PET or SPECT imaging of the distribution of Pgp are disclosed. The tracers are metalloprobes that can comprise a radioactive metal ion such as | 11-20-2014 |
20140330394 | METHODS AND SYSTEMS FOR CONTROLLING BODY PARTS AND DEVICES USING IPSILATERAL MOTOR CORTEX AND MOTOR RELATED CORTEX - A system for controlling a body part includes a number of sensing devices that sense signals from a hemisphere of a brain. A signal translating unit translates the signals into a command signal for controlling the body part, which is on a same side of the body as the hemisphere of the brain. A prosthetic device receives the command signal from the signal translating unit and manipulates the body part in response to the command signal. | 11-06-2014 |
20140309478 | DEVICES AND METHODS FOR TREATMENT OF CANCERS - Devices and methods for brachytherapy treatment are disclosed. One aspect is a poly(methyl methacrylate) apparatus for brachytherapy treatment at the vaginal apex. Another aspect is a poly(methyl methacrylate) apparatus for brachytherapy treatment in the distal two-thirds of the vagina. Another aspect is a poly(methyl methacrylate) apparatus for brachytherapy treatment of cancers that are offset from the vaginal apex. Other aspects include methods for guiding needles for treatment of cancers at the vaginal apex, in the distal two-thirds of the vagina, and that are offset from the vaginal apex. | 10-16-2014 |
20140309443 | NEUROACTIVE 17(20)-Z-VINYLCYANO-SUBSTITUTED STEROIDS, PRODRUGS THEREOF, AND METHODS OF TREATMENT USING SAME - The present disclosure is generally directed to neuroactive 17(20)-Z-vinylcyano-substituted compound of Formula (I) and (II), as referenced herein, and pharmaceutically acceptable salts thereof, for use as, for example, an anesthetic, and/or in the treatment of disorders relating to GABA function and activity. The present disclosure is further directed to pharmaceutical compositions comprising such compounds. | 10-16-2014 |
20140303226 | KCNQ CHANNELS AS THERAPEUTIC TARGETS - The present disclosure relates to methods and compositions for modulating the activity of KCNQ channels as a means for reducing the effects of aberrant KCNQ channel function associated with epilepsy, deafness and arrhythmias including but not limited to, Long-QT syndrome (“LQTS”), and atrial fibrillation. The present disclosure also relates to the discovery of certain regions of KCNQ channels that interact with various channel stimulating molecules such as, ATP, and PIP | 10-09-2014 |
20140273004 | MOLECULES AND METHODS FOR ITERATIVE POLYPEPTIDE ANALYSIS AND PROCESSING - Reagents and methods for the digital analysis of proteins or peptides are provided. Specifically provided herein are proteins for identifying the N-terminal amino acid or N-terminal phosphorylated amino acid of a polypeptide. Also, an enzyme for use in the cleavage step of the Edman degradation reaction and a method for using this enzyme are described. | 09-18-2014 |
20140249120 | NEUROACTIVE 13, 17-SUBSTITUTED STEROIDS AS MODULATORS FOR GABA TYPE-A RECEPTORS - The present disclosure is generally directed to neuroactive 13,17-substituted steroids as referenced herein, and pharmaceutically acceptable salts thereof, for use as, for example, an anesthetic, and/or in the treatment of disorders relating to GABA function and activity. The present disclosure is further directed to pharmaceutical compositions comprising such compounds. | 09-04-2014 |
20140242609 | Diagnosis and treatment of kidney stones, methods and compositions therefor - Methods of detecting, diagnosing, monitoring and treating kidney stones are disclosed. In some embodiments, methods of detecting, diagnosing or monitoring kidney stones comprise contacting a urine sample with anti-Claudin-14 antibody, and detecting quantity of a complex comprising Claudin-14 and the antibody, wherein an increase compared to control levels is diagnostic for kidney stones. In some embodiments, methods further comprise testing a second sample at a second time point to detect increased kidney stones. In some embodiments, methods of treating kidney stone disease comprise administering an miR-9 mimic or an miR-374 mimic. In some embodiments, methods comprise administering an inhibitor of CaSR signaling. In some embodiments, methods comprise administering a HDAC inhibitor. In some embodiments methods of treating hyperparathyroidism and hypercalcemia are disclosed, comprising administering an agonist of CaSR. Methods of abrogating CaSR-mediated regulation of claudin-14, microRNAs and urinary Ca++ excretion are disclosed, comprising administering a calcineurin inhibitor. | 08-28-2014 |
20140235600 | NEUROACTIVE 19-ALKOXY-17-SUBSTITUTED STEROIDS, PRODRUGS THEREOF, AND METHODS OF TREATMENT USING SAME - The present disclosure is generally directed to neuroactive 19-alkoxy-17-substituted steroids as referenced herein, and pharmaceutically acceptable salts thereof, for use as, for example, an anesthetic, and/or in the treatment of disorders relating to GABA function and activity. The present disclosure is further directed to pharmaceutical compositions comprising such compounds. | 08-21-2014 |
20140178855 | Murine Astroviruses - Novel murine astroviruses, and methods of detecting the viruses are disclosed. Also disclosed are uses of the viruses and infected animals as model systems for discovery and development of vaccines and therapies for diseases caused by or associated with astrovirus infection, including human astrovirus-based diseases. | 06-26-2014 |
20140158787 | ELECTROHYDRODYNAMIC ATOMIZATION NOZZLE EMITTING A LIQUID SHEET - Embodiments for producing un-agglomerated, monodisperse droplets using a liquid sheet are provided. Nozzles with exit slit openings shape a spray liquid into a thin liquid sheet as the spray liquid exits from the slit opening. Stable multi-jet operation is achieved by including notches along the edge of the slit. The notches separate the liquid sheet into multiple jets to provide anchoring and stable multi jet operation. In some embodiments, the liquid sheet electrospray techniques and nozzles described herein provide high mass throughput and versatile multiplexing spray systems while reducing the engineering effort and high manufacturing cost | 06-12-2014 |
20140147929 | Nanothermometer, Methods and Uses Therefor - A nanothermometer is disclosed. In various embodiments, a nanothermometer comprises a nanoparticle such as a gold nanoparticle, a fluorophore, and a linker, such as a peptide linker, extending between the nanoparticle and the fluorophore, whereby the fluorophore is self-quenched. The linker can comprise one or more cysteines. An unheated thermometer shows little or no fluorescence. Upon heating, fluorophore-linker conjugates are released from the nanoparticle, thereby unquenching the fluorescence. An increase in fluorescence results. In some embodiments, the increase in fluorescence can be irreversible. Methods of measuring temperature of a sample such as a biological sample, and methods of synthesizing a nanothermometer, are also disclosed. A molecular thermometer is also disclosed. | 05-29-2014 |
20140020132 | PLANTS HAVING INCREASED DESICCATION TOLERANCE, INCREASED DROUGHT TOLERANCE OR INCREASED WATER USE EFFICIENCY - A transgenic plant engineered to have increased desiccation tolerance, increased drought tolerance or increased water use efficiency, the plant transformed with an artificial DNA construct comprising a transcribable nucleic acid molecule encoding a polypeptide requiring both ABA and ABI3 to influence desiccation tolerance. Also provided are DNA constructs and methods of producing a transgenic plant engineered to have increased desiccation tolerance, increased drought tolerance or increased water use efficiency. | 01-16-2014 |
20140011890 | METHODS AND COMPOSITIONS FOR TREATING NEUROPATHIES - Methods of treating or preventing axonal degradation in neuropathic diseases and neurological disorders in mammals are disclosed. The methods can comprise administering to the mammal an effective amount of an agent that acts at least in part by increasing sirtuin AMPK activity, LKB | 01-09-2014 |
20130317090 | INHIBITION OF CHOROIDAL NEOVASCULARIZATION - Methods of treatment of diseases that include or are characterized by inappropriate or pathological neovascularization are disclosed. These diseases include diseases of the eye, such as diabetic retinopathy, retinopathy of prematurity, and choroidal neovascularization which can occur in age-related macular degeneration (AMD). Disclosed methods include administering agents that cause directly or indirectly upregulation of the ABCA1 transporter protein in macrophages. These agents include, without limitation, LXR agonists. In some embodiments, inhibitors of CETP expression or activity can also be effective. Administration routes can include, without limitation, intraocular, periocular, or systemic administration. | 11-28-2013 |
20130315825 | TRICYCLIC HETEROAROMATIC COMPOUNDS AS ALPHA-SYNUCLEIN LIGANDS - Derivatives of phenothiazine, phenoxazine, and phenazine compounds and their use as α-synuclein ligands are described. Also described are methods of using these compounds and their radiolabeled analogs for the detection, monitoring, and treatment of synucleinopathies, including Parkinson's disease. | 11-28-2013 |
20130302270 | TUMOR TARGETED TNF-RELATED APOPTOSIS INDUCING LIGAND FUSION POLYPEPTIDE, METHODS AND USES THEREFOR - Fusion polypeptides comprising a TRAIL trimer and a targeting domain are disclosed. The targeting domain can be, in some embodiments, a sequence that binds MUC16, which is prevalent on some tumor cells such as pancreatic and ovarian tumor cells. A sequence that binds MUC 16 can be mesothelin or a MUC16-binding fragment thereof, such as amino acids 1-64 of mesothelin. A fusion polypeptide of the present teachings can induce apoptosis in a target cell such as a MUC16-expressing cancer cell. Also disclosed are nucleic acids encoding the fusion polypeptides, and methods of use of the fusion polypeptides and nucleic acids. | 11-14-2013 |
20130273430 | SYNTHESIS OF SUBMICROMETER TO MICROMETER-SIZED CATHODE MATERIALS - A method of producing submicrometer- to micrometer-sized spherical particles, the method comprising dissolving a lithium salt and a metal salt in water or alcohol forming a precursor solution, spraying the precursor solution to form fine aerosolized droplets, flowing the aerosolized droplets into a pyro lysis flame producing submicrometer- to micrometer-sized spherical particles. The submicrometer- to micrometer-sized spherical lithium-metal oxide powders produced are cathode materials for Li-ion batteries. | 10-17-2013 |
20130230452 | CELL PERMEABLE NANOCONJUGATES OF SHELL-CROSSLINKED KNEDEL (SCK) AND PEPTIDE NUCLEIC ACIDS ("PNAs") WITH UNIQUELY EXPRESSED OR OVER-EXPRESSED mRNA TARGETING SEQUENCES FOR EARLY DIAGNOSIS AND THERAPY OF CANCER - A functional biologically active particle conjugate useful for diagnosis and treating cancer as a bioportal comprises a nanoscale particle having associated therewith an intracellular targeting ligand comprising a PNA, or another nuclease resistant oligonucleotide analog such as MOE-mRNA (2′-methoxyethyl mRNA) or LNA (locked nucleic acid), having a sequence that binds selectively to an uniquely expressed or overexpressed mRNA specific to the cancer or disease state in a living mammal. In one aspect the uniquely overexpressed target specific to the cancer or disease state is the unr mRNA which can be targeted by the antisense sequence PNA50. | 09-05-2013 |
20130203838 | METHODS AND COMPOSITIONS FOR INHIBITION OF AXONAL DEGENERATION BY MODULATION OF THE DLK/JNK PATHWAY - Methods of reducing Wallerian degeneration are disclosed. These methods comprise inhibiting expression or activity of a mixed lineage kinase such as a dual leucine-zipper-bearing kinase (DLK), inhibiting expression or activity of a molecule acting downstream from DLK, such as a c-Jun N-terminal kinase (JNK), or a combination thereof. Further disclosed are methods of screening candidate compounds for DLK inhibition activity. These methods comprise providing a neuronal culture comprising a plurality of axons; contacting the culture with a candidate compound and with an axon degeneration-triggering agent; and comparing axonal degeneration in the culture to a control culture comprising the axon degeneration-triggering agent but not the candidate compound. | 08-08-2013 |
20130203133 | BUOYANT TRIACYLGLYCEROL-FILLED GREEN ALGAE AND METHODS THEREFOR - Cultures of | 08-08-2013 |
20130199299 | QUANTIFICATION OF OPTICAL ABSORPTION COEFFICIENTS USING ACOUSTIC SPECTRA IN PHOTOACOUSTIC TOMOGRAPHY - Accurately quantifying optical absorption coefficient using acoustic spectra of photoacoustic signals. Optical absorption is closely associated with many physiological parameters, such as the concentration and oxygen saturation of hemoglobin, and it can be used to quantify the concentrations of non-fluorescent molecules. A sample is illuminated by, for example, a pulsed laser and following the absorption of optical energy, a photoacoustic pressure is generated via thermo-elastic expansion. The acoustic waves then propagate and are detected by a transducer. The optical absorption coefficient of the sample is quantified from spectra of the measured photoacoustic signals. Factors, such as system bandwidth and acoustic attenuation, may affect the quantification but are canceled by dividing the acoustic spectra measured at multiple optical wavelengths. | 08-08-2013 |
20130197663 | BIOMEDICAL PATCHES WITH ALIGNED FIBERS - A structure of aligned (e.g., radially and/or polygonally aligned) fibers, and systems and methods for producing and using the same. One or more structures provided may be created using an apparatus that includes one or more first electrodes that define an area and/or partially circumscribe an area. For example, a single first electrode may enclose the area, or a plurality of first electrode(s) may be positioned on at least a portion of the perimeter of the area. A second electrode is positioned within the area. Electrodes with rounded (e.g., convex) surfaces may be arranged in an array, and a fibrous structure created using such electrodes may include an array of wells at positions corresponding to the positions of the electrodes. | 08-01-2013 |
20130177990 | METHODS OF DETERMINING EFFICACY OF CYCLODEXTRIN THERAPY - Disclosed are methods for determining efficacy of a cyclodextrin therapy in a subject afflicted with a disorder involving oxysterol accumulation. These methods comprise: obtaining a first body fluid sample from the subject prior to cyclodextrin administration; administering cyclodextrin; obtaining at least one second body fluid sample after the cyclodextrin administration; subjecting the body fluid samples to chromatography-mass spectroscopy analysis to determine concentration of 24-hydroxycholesterol and/or cholestane-3β,5α,6β-triol; and determining magnitude of difference between the 24-hydroxycholesterol and/or cholestane-3β,5α,6β-triol concentration of the body fluid samples, whereby an increase or stabilization of 24-hydroxycholesterol concentration, or a reduction of cholestane-3β,5α,6β-triol concentration in the at least one second sample compared to the first sample, indicates efficacy of the cyclodextrin therapy. | 07-11-2013 |
20130155492 | METAMATERIALS WITH ENHANCED NONLINEARITY - Embodiments provide metamaterials having an enhanced nonlinear response to light. The metamaterials are artificially manufactured materials having a nonlinear response to light greater than that typically found in naturally occurring materials. A two-dimensional periodic metal-dielectric array can be mathematically mapped as an effective uniform dielectric slab with enhanced optical nonlinearity. The enhanced nonlinearity is controlled by the geometry of the array. Further, the configuration of the array can be applied to form three-dimensional structures having an enhanced nonlinear response to light. | 06-20-2013 |
20130137127 | DATING BLOODSTAINS AND BIOLOGICAL FLUIDS WITH FLUORESCENCE LIFETIME TECHNIQUES - Methods of aging biological samples through the use of fluorescence lifetime are disclosed herein. These methods provide aging of samples such as bloodstains using endogenous fluorophores and conformational protein changes. Advantageously, the methods provide the average fluorescence lifetime across a region of interest in a biological sample, thereby minimizing problems with sampling and providing accurate results. | 05-30-2013 |
20130131576 | CATHETER ASSEMBLY FOR USE WITH SHUNT SYSTEMS AND METHOD OF USING SAME - A catheter assembly for inserting in a fluid filled space in a body includes a main body having a first end portion and a second end portion. The first end portion is positionable within the fluid filled space and the second end portion is adapted to extend outward from the fluid filled space when the first end portion is positioned within the fluid filled space. The catheter assembly also includes a catheter tip that is connected to the second end portion. The catheter tip includes a housing having a cavity defined therein. The catheter tip also includes a rotating element positioned within the cavity. The rotating element is configured to rotate within the cavity to facilitate movement of the first end portion of the main body within the fluid filled space. | 05-23-2013 |
20130123607 | SYSTEM AND METHOD FOR TASK-LESS MAPPING OF BRAIN ACTIVITY - A computing device for use in a system for mapping brain activity of a subject includes a processor. The processor is programmed to select a plurality of measurements of brain activity that is representative of at least one parameter of a brain of the subject during a resting state. Moreover, the processor is programmed to compare at least one data point from each of the measurements with a corresponding data point from a previously acquired data set from at least one other subject. The processor is also programmed to produce at least one map for each of the measurements based on the comparison of the resting state data point and the corresponding previously acquired data point. The processor may also be programmed to categorize the brain activity in a plurality of networks in the brain based on the map. | 05-16-2013 |
20130079522 | DIHYDROETHIDINE ANALOGUES AND USES THEREOF - Tracers for imaging distribution of reactive oxygen species (ROS) are disclosed. The tracers include radiolabeled dihydroethidine (DHE) analogues. Further disclosed are uses of the compounds, including methods of imaging tissue distribution of ROS in vivo by positron emission tomography (PET). Methods of synthesizing the compounds are also disclosed. | 03-28-2013 |
20130023004 | FLUOROGENIC SUBSTRATE FOR ADAMTS13 - Disclosed are fluorogenic substrates for measuring ADAMTS13 activity or ADAMTS13 inhibitor activity. Substrates can comprise an oligopeptide which can consist of up to 80 amino acids of sequence of von Willebrand Factor (VWF). The oligopeptide can include modifications of sequence of VWF, including an amino-terminal glycine, a scissile Y-M peptide, and a cysteine substitution located from 1 to 12 amino acids from the scissile Y-M in the carboxy terminal direction. A substrate can further comprise a fluorophore and a fluorescence quencher bound to the oligopeptide on opposite sides of the scissile Y-M peptide, wherein the fluorescence quencher is not identical to the fluorophore. An oligopeptide can be encoded by a nucleic acid sequence which can also encode a His tag. An oligopeptide can be expressed in a cell or microorganism. Also disclosed are methods of using a fluorogenic substrate to measure ADAMTS13 activity or ADAMTS13 inhibitor activity. | 01-24-2013 |
20120301439 | INHIBITION OF CHOROIDAL NEOVASCULARIZATION - Methods of treatment of diseases that include or are characterized by inappropriate or pathological neovascularization are disclosed. These diseases include diseases of the eye, such as diabetic retinopathy, retinopathy of prematurity, and choroidal neovascularization which can occur in age-related macular degeneration (AMD). Disclosed methods include administering agents that cause directly or indirectly upregulation of the ABCA1 transporter protein in macrophages. These agents include, without limitation, LXR agonists. In some embodiments, inhibitors of CETP expression or activity can also be effective. Administration routes can include, without limitation, intraocular, periocular, or systemic administration. | 11-29-2012 |
20120295957 | PREVENTION OF TISSUE ISCHEMIA AND RELATED COMPOSITIONS - Provided herein are compositions for preventing, ameliorating, and/or reducing tissue ischemia and/or tissue damage due to ischemia, increasing blood vessel diameter, blood flow and tissue perfusion in the presence of vascular disease including peripheral vascular disease, atherosclerotic vascular disease, coronary artery disease, stroke and influencing other conditions, by suppressing CD47 and/or blocking TSP1 and/or CD47 activity or interaction. Influencing the interaction of CD47-TSP1 in blood vessels allows for control of blood vessel diameter and blood flow, and permits modification of blood pressure and cardiac function. Under conditions of decreased blood flow, for instance through injury or atherosclerosis, blocking TSP1-CD47 interaction allows blood vessels to dilate and increases blood flow, tissue perfusion and tissue survival. | 11-22-2012 |
20120295956 | PREVENTION OF TISSUE ISCHEMIA AND RELATED METHODS - Provided herein are methods for preventing, ameliorating, and/or reducing tissue ischemia and/or tissue damage due to ischemia, increasing blood vessel diameter, blood flow and tissue perfusion in the presence of vascular disease including peripheral vascular disease, atherosclerotic vascular disease, coronary artery disease, stroke and influencing other conditions, by suppressing CD47 and/or blocking TSP1 and/or CD47 activity or interaction. Influencing the interaction of CD47-TSP1 in blood vessels allows for control of blood vessel diameter and blood flow, and permits modification of blood pressure and cardiac function. Under conditions of decreased blood flow, for instance through injury or atherosclerosis, blocking TSP1-CD47 interaction allows blood vessels to dilate and increases blood flow, tissue perfusion and tissue survival. | 11-22-2012 |
20120292517 | REAL-TIME IMAGING DOSIMETER SYSTEMS AND METHOD - A radiation therapy system including a linear accelerator configured to emit a beam of radiation and a dosimeter configured to detect in real-time the beam of radiation emitted by the linear accelerator. The dosimeter includes at least one linear array of scintillating fibers configured to capture radiation from the beam at a plurality of independent angular orientations, and a detection system coupled to the at least one linear array, the detection system configured to detect the beam of radiation by measuring an output of the scintillating fibers. | 11-22-2012 |
20120289416 | METHODS AND KITS USED IN ASSESSING CANCER RISK - Methods of assessing the risk of recurrence of endometrial cancer on the basis of the presence or absence of mutations in FGFR2 are disclosed. | 11-15-2012 |
20120282522 | Spray Pyrolysis Synthesis of Mesoporous Positive Electrode Materials for High Energy Lithium-Ion Batteries - A lithium metal oxide positive electrode material useful in making lithium-ion batteries that is produced using spray pyrolysis. The material comprises a plurality of metal oxide secondary particles that comprise metal oxide primary particles, wherein the primary particles have a size that is in the range of about 1 nm to about 10 μm, and the secondary particles have a size that is in the range of about 10 nm to about 100 μm and are uniformly mesoporous. | 11-08-2012 |
20120275262 | SECTION-ILLUMINATION PHOTOACOUSTIC MICROSCOPY WITH ULTRASONIC ARRAY DETECTION - Imaging systems, probes for imaging systems, and methods for noninvasive imaging are disclosed. In one example, a probe for use with an imaging system includes a slit configured to spatially filter a light beam from a light source. The probe includes a focusing device configured to cylindrically focus the spatially filtered light beam into an object, and an ultrasound transducer array configured to detect a photoacoustic signal emitted by the object in response to the cylindrically focused light beam. | 11-01-2012 |
20120271149 | INSERT DEVICE FOR ENHANCING PET AND MRI IMAGES - Insert devices that include a RF surface coil and gamma-ray photon detector array for enhancing PET and MRI images produced from integrated PET-MRI scanners are disclosed. Integrated PET-MRI scanners that include such insert devices as well of methods for scanning an object by use of such devices are also disclosed. | 10-25-2012 |
20120215801 | Method and Apparatus for Adjustable Data Matching - A method and apparatus for performing a matching operation on data are disclosed. With an exemplary embodiment, a programmable logic device can be used to search for data of interest to an application, where the programmable logic device processes streaming data against a data key to generate a signal indicative of a similarity between the streaming data and the data key and compares the generated signal with a defined threshold to thereby determine whether the streaming data is deemed a match to the data key, wherein the threshold is adjustable to control whether the programmable logic device performs an approximate match operation or an exact match operation, and further to control, for an approximate match operation, a degree of approximate matches returned by the approximate match operation. | 08-23-2012 |
20120202233 | Methods and uses of KSR kinase, and mutations thereof - Mutant KSR proteins are disclosed. The mutants include single amino acid substitutions, leading to either a loss of kinase activity or a loss of scaffolding activity. Also disclosed are methods of screening compounds for inhibitors of KSR kinase activity or KSR scaffolding activity. In some embodiments, the screening methods include protein complementation assays in which nucleic acids encoding fusion constructs comprising enzyme portions and kinase dimerization domains are expressed in cells. Inhibitors of dimerization can be indicated by loss of enzyme activity. | 08-09-2012 |
20120190578 | Plasma Complement Components as Expression Markers for Age-Related Macular Degeneration and Related Phenotypes - The present invention is directed to systems and method for predicting risk of AMD or a susceptibility to AMD in a patient by detecting elevated serum or plasma levels of C3, CFB or CFH and other complement factor polypeptides, wherein devated levels certain complement factors, genetic risk factors, medical risk factors, behavioral and environmental risk factors are associated with are indicative of susceptibility for or an increased risk of developing AMD, or an increased risk of progression of AMD in the patient. | 07-26-2012 |
20120184451 | LABEL-FREE DETECTION OF RENAL CANCER - Natural and/or synthetic antibodies for specific proteins are adhered to nanoparticles. The nanoparticles are adhered to a substrate and the substrate is exposed to a sample that may contain the specific proteins. The substrates are then tested with surface enhanced Raman scattering techniques and/or localized surface plasmon resonance techniques to quantify the amount of the specific protein in the sample. | 07-19-2012 |
20120171119 | PEGYLATED FLUOROBENZAMIDE ANALOGUES, THEIR SYNTHESIS AND USE IN DIAGNOSTIC IMAGING - Pegylated fluoroalkoxybenzamide compounds which selectively bind Sigma-2 receptors are disclosed. These compounds, when labeled with a positron-emitting radioisotope such as | 07-05-2012 |
20120130922 | Method and Apparatus for Processing Financial Information at Hardware Speeds Using FPGA Devices - A method and apparatus use hardware logic deployed on a reconfigurable logic device to process a stream of financial information at hardware speeds. The hardware logic can be configured to perform data reduction operations on the financial information stream. Examples of such data reductions operations include data processing operations to compute a latest stock price, a minimum stock price, and a maximum stock price. | 05-24-2012 |
20120128590 | NANOPARTICLE DELIVERY SYSTEMS FOR MEMBRANE-INTEGRATING PEPTIDES - Compositions which comprise emulsions of nanoparticles for delivery of membrane-integrating peptides are described. The nanoparticles comprise a liquid hydrophobic core coated with a lipid/surfactant layer which contains the membrane-integrating peptides. Methods to use such compositions are also described. | 05-24-2012 |
20120116998 | Method and Apparatus for Processing Financial Information at Hardware Speeds Using FPGA Devices - A method and apparatus use a reconfigurable logic device to process a stream of financial information at hardware speeds. The reconfigurable logic device can be configured to perform data processing operations on the financial information stream. Examples of such data processing operations include data processing operations to compute a latest stock price, a minimum stock price, and a maximum stock price. | 05-10-2012 |
20120115747 | Methods Of Renal Cancer Detection - Disclosed are methods for detecting, diagnosing or monitoring a renal cancer in a subject. The methods include detecting quantity of one or more polypeptides or fragments thereof comprised by body fluid such as urine, wherein the one or more polypeptides or fragments thereof, can be present at elevated levels in a subject with a kidney cancer, as compared to a subject without a kidney cancer. Non-limiting examples of such polypeptides include aquaporin-1, adipose differentiation-related protein and paired box protein-2. Antibody probes can be used to detect or quantify the polypeptides. In some embodiments, mass spectroscopy can be used to detect or quantify the polypeptides, or to identify a polypeptide in a body fluid sample from a subject with a kidney cancer. | 05-10-2012 |
20120110316 | Intelligent Data Storage and Processing Using FPGA Devices - A re-configurable logic device such as a field programmable gate array (FPGA) can be used to deploy a data processing pipeline, the pipeline comprising a plurality of pipelined data processing engines, the plurality of pipelined data processing engines being configured to perform processing operations, wherein the pipeline comprises a multi-functional pipeline, and wherein the re-configurable logic device is further configured to controllably activate or deactivate each of the pipelined data processing engines in the pipeline in response to control instructions and thereby define a function for the pipeline, each pipeline function being the combined functionality of each activated pipelined data processing engine in the pipeline. | 05-03-2012 |
20120109849 | Intelligent Data Storage and Processing Using FPGA Devices - A re-configurable logic device such as a field programmable gate array (FPGA) can be used to deploy a data processing pipeline, the pipeline comprising a plurality of pipelined data processing engines, the plurality of pipelined data processing engines including a data reduction engine, the plurality of pipelined data processing engines being configured to perform processing operations, wherein the pipeline comprises a multi-functional pipeline, and wherein the re-configurable logic device is further configured to controllably activate or deactivate each of the pipelined data processing engines in the pipeline in response to control instructions and thereby define a function for the pipeline, each pipeline function being the combined functionality of each activated pipelined data processing engine in the pipeline. | 05-03-2012 |
20120100186 | NANOPARTICULATE-BASED CONTRACEPTIVE/ANTI-HIV COMPOSITION AND METHODS - Nanoparticulate compositions which employ membrane-integrating peptides to effect contraception and/or protection against infection by sexually transmitted virus are described. | 04-26-2012 |
20120100073 | PET RADIOTRACERS FOR IMAGING FATTY ACID METABOLISM AND STORAGE - Fatty acid analogue (FAA) molecules comprising positron-emitting radionuclides, salts thereof, and FAA-triglycerides are disclosed. Also disclosed are methods of synthesis, and methods of imaging distribution and metabolism of fatty acids and fatty acid triglycerides. | 04-26-2012 |
20120076758 | ANTIBODIES AGAINST WEST NILE VIRUS AND THERAPEUTIC AND PROPHYLACTIC USES THEREOF - The present invention relates to compositions comprising antibodies or fragments thereof that immunospecifically bind to one or more antigens of a flavivirus, particularly of West Nile Virus (WNV), and methods for preventing, treating or ameliorating symptoms associated with a flavivirus, particularly of West Nile Virus (WNV), infection utilizing said compositions. In particular, the present invention relates to methods for preventing, treating or ameliorating symptoms associated with WNV infection, said methods comprising administering to a human subject an effective amount of one or more antibodies or fragments thereof that immunospecifically bind to a WNV antigen. The present invention also relates to detectable or diagnostic compositions comprising antibodies or fragments thereof that immunospecifically bind to a WNV antigen and methods for detecting or diagnosing WNV infection utilizing said compositions. | 03-29-2012 |
20120068084 | RADIATION DOSIMETERS FOR QUANTIFYING THE DOSE OF RADIATION APPLIED DURING RADIATION THERAPY - Radiation dosimeters containing thin KCl:Eu | 03-22-2012 |
20120028793 | DUAL-OXIDE SINTER RESISTANT CATALYST - A catalyst material for use at elevated temperatures is provided. The material can include a plurality of fibers and a plurality of particles supported on the fibers. In addition, a porous layer can cover the plurality of particles and allow for process fluid to come into contact with the particles, and yet retard sintering of the particles at elevated temperatures is present. The plurality of fibers can be a plurality of nanofibers which may or may not be oxide nanofibers. The particles can be metallic nanoparticles and the porous layer can be a porous oxide layer. | 02-02-2012 |
20120021534 | MARKERS FOR BRAIN DAMAGE - Methods to identify markers for brain damage using fresh brain tissue and methods and compositions for detecting these markers are disclosed. | 01-26-2012 |
20110312919 | INHIBITORS OF TYROSINE KINASE RECEPTOR DIMERIZATION - The teachings relate to methods of identifying inhibitors of dimerization of tyrosine receptor kinases such as EGFR. The methods comprise providing, on a digital computer, a molecular model comprising a complex of extracellular dimerization domains of an RTK, docking a chemical databases to the molecular model, scoring the compounds comprised by the database, and identifying one or more high-scoring compounds. The methods further comprise testing a compound for RTK inhibitory activity in vitro, and testing a compound for specificity as an RTK inhibitor. Also disclosed are compounds selected by the described methods, and methods of treatment using the compounds. Two compounds (NSC11241 and NSC56452) are disclosed that inhibit EGF receptor kinase activation in a dose-dependent manner. | 12-22-2011 |
20110311519 | METHODS OF TREATMENT OF BONE DEGENERATIVE DISEASES - Methods of reducing bone loss and treating degenerative bone diseases such as osteoporosis are disclosed. The methods comprise administration of an agent that inhibits signaling through the IL-17 pathway, such as an antibody or a quinazoline analogue such as halofuginone. | 12-22-2011 |
20110311447 | Compounds comprising 4-benzoylpiperidine as a Sigma-1-selective ligand - Bipiperidinyl compounds and salts thereof are disclosed. The compounds include high affinity ligands for σ | 12-22-2011 |
20110300629 | TRAIL trimers, methods and uses therefor - Disclosed are TNF-related apoptosis-inducing ligand (TRAIL) trimers (TR3) and nucleic acids encoding covalently linked TRAIL trimers. A TRAIL trimer can have greater stability compared to native TRAIL, and can retain the native killing ability of TRAIL. Target specificity of a TR3 can be shown by blocking its activity with soluble death receptor 5 (DR5-Fc). Also disclosed are modified TRAIL trimers and nucleic acids encoding them. These modifications include additional functional domains, such as antibody fragments (scFvs). A TR3 comprising an additional functional domain can allow for cell-specific delivery of the TR3. In some configurations, a modification such as the addition of a functional domain can be stoichiometrically controlled. In some configurations, a modification can be inconsequential with regard to the bioactivity of TRAIL. In various embodiments, a TR3, including a modified TR3, can be a cancer-selective drug. In some configurations, a TR3 that comprises an additional biologically active moiety such as a functional domain of a protein can have fewer off-target toxicities compared to TRAIL alone. In some configurations, a TR3 that comprises an additional biologically active moiety such as a functional domain of a protein can have enhanced killing capacities compared to the moiety alone. In some aspects, TR3 activity can be targeted to an RBC membrane. The inventors disclose TR3-decorated RBCs that target cell killing in a model of pancreatic cancer. | 12-08-2011 |
20110300071 | TARGETING NPR-C IN ANGIOGENESIS AND ATHEROSCLEROSIS WITH A C-TYPE ATRIAL NATRIURETIC FACTOR (CANF)-COMB NANOCOMPLEX - Tracers are disclosed comprising an amphiphilic comb-like nanostructure conjugated with an oligopeptide such as a fragment of a natriuretic peptide, and a signaling moiety such as a positron-emitting radionuclide. A fragment of a natriuretic peptide comprises Arg-Ile-Asp-Arg-Ile (SEQ ID NO:1). Further disclosed are methods of imaging distribution of C-type atrial natriuretic peptide receptors and methods of imaging angiogenesis and atherosclerosis by PET scanning or MRI using a tracer. | 12-08-2011 |
20110250145 | BIOLUMINESCENCE IMAGING OF MYELOPEROXIDASE ACTIVITY IN VIVO, METHODS, COMPOSITIONS AND APPARATUSES THEREFOR - Methods of imaging distribution of myeloperoxidase activity in a subject are disclosed. These methods include the use of bioluminescent substrates, including luminol and wavelength-shifted analogues of luminol. Bioluminescent myeloperoxidase substrates that emit light at longer wavelengths compared to luminol are shown to be useful for imaging myeloperoxidase activity in vivo. The disclosed methods can be used for imaging sites of inflammation and other pathological conditions associated with abnormal levels of MPO activity in vivo. Methods of synthesis of luminol analogues are also disclosed. | 10-13-2011 |
20110231446 | Method and Apparatus for Performing Similarity Searching - A system and method for performing similarity searching is disclosed. This includes a programmable logic device configured to include a pipeline that comprises a matching stage, the matching stage being configured to receive a data stream comprising a plurality of possible matches between a plurality of data strings and a plurality of substrings of a query string. The pipeline may further include an ungapped extension prefilter stage located downstream from the matching stage, the prefilter stage being configured to shift through pattern matches between the data strings and the plurality of substrings of a query string and provide a score so that only pattern matches that exceed a user defined score will pass downstream from the prefilter stage. The matching stage may include at least one Bloom filter. | 09-22-2011 |
20110230662 | RADIOLABELLED FLUOROBENZAMIDE ANALOGUES, THEIR SYNTHESIS AND USE IN DIAGNOSTIC IMAGING - Fluoroalkoxybenzamide compounds which selectively bind Sigma-2 receptors are disclosed. These compounds, when labelled with | 09-22-2011 |
20110158986 | HUMANIZED ANTIBODIES THAT SEQUESTER AMYLOID BETA PEPTIDE - A method to treat conditions characterized by formation of amyloid plaques both prophylactically and therapeutically is described. The method employs humanized antibodies which sequester soluble Aβ peptide from human biological fluids or which preferably specifically bind an epitope contained within position 13-28 of the amyloid beta peptide Aβ. | 06-30-2011 |
20110124205 | TUNING OF PHOTO-ABSORPTION MATERIALS THROUGH USE OF MAGNETIC FIELDS - The disclosure relates to using magnetic fields for the purposes of modifying the absorption characteristics of materials, such as semiconductor materials, to both tune the materials to specific wavelengths and to enhance the absorption of the materials by concentrating the continuum of states of the conduction and valence bands into magnetic field-dependent Landau levels. | 05-26-2011 |
20110123510 | Methods of Affecting Biological Function Through Circadian Clock Feedback Cycle by NAMPT-Mediated NAD+ Biosynthesis - The present invention relates to methods of regulating biological functions in a mammal that are mediated, at least in part, by the circadian clock. | 05-26-2011 |
20110020294 | INDUCEMENT OF ORGANOGENETIC TOLERANCE FOR PANCREATIC XENOTRANSPLANT - Provided herein is an approach to establish organogenetic tolerance via prior transplantation of pig embryonic pancreas, thereby enabling subsequent implantation of porcine islets in a subject without the need for immune-suppression. In one aspect of the invention, porcine pancreatic primordia are implanted into a mammalian subject, and after a period of time sufficient to induce tolerance, porcine islet cells are implanted in the subject. | 01-27-2011 |
20100330121 | RECOMBINANT ALPHAVIRUS-BASED VECTORS WITH REDUCED INHIBITION OF CELLULAR MACRO-MOLECULAR SYNTHESIS - Isolated nucleic acid molecules are disclosed, comprising an alphavirus nonstructural protein gene which, when operably incorporated into a recombinant alphavirus particle, eukaryotic layered vector initiation system, or RNA vector replicon, has a reduced level of vector-specific RNA synthesis, as compared to wild-type, and the same or greater level of proteins encoded by RNA transcribed from the viral junction region promoter, as compared to a wild-type recombinant alphavirus particle. Also disclosed are RNA vector replicons, alphavirus vector constructs, and eukaryotic layered vector initiation systems which contain the above-identified nucleic acid molecules. | 12-30-2010 |
20100317638 | Neuroactive 13,24-Cyclo-18,21-Dinorcholanes and Structurally Related Pentacylic Steroids - Novel pentacyclic steroids and pentacyclic D-homosteroids comprising: (i) the tetracyclic steroid ring system or tetracyclic D-homosteroid ring system, respectively; (ii) a C(3) substituent selected from the group consisting of (a) a hydroxyl or carboxyl in the α-configuration and (b) a sulfate or other negatively charged moiety; and (iii) a fused fifth ring, the fused fifth ring comprising a hydrogen bond acceptor, and (a) in the case of the pentacyclic steroid the C(13) and C(17) carbons, or (b) in the case of the pentacyclic D-homosteroid the C(13) and C(17a) carbons, having utility as anesthetics and in the treatment of disorders relating to GABA function and activity. | 12-16-2010 |
20100311807 | METHODS FOR IDENTIFYING DIABETES AND OBESITY THERAPEUTICS - The invention relates to inhibition of Par-1b kinase activity for treating disorders including diabetes and obesity. The invention also relates to screening for compounds or compositions that inhibit the kinase activity of Par-1b protein, which compounds and compositions are useful in the treatment of diabetes and obesity, as well as preparing compounds for treatment of diabetes and obesity. | 12-09-2010 |
20100307593 | SYNTHESIS OF NANOSTRUCTURED PHOTOACTIVE FILMS WITH CONTROLLED MORPHOLOGY BY A FLAME AEROSOL REACTOR - An improved process for the preparation of nanostructured metal species-based films in a flame aerosol reactor is provided. The process comprises combusting vaporized metal precursor, vaporized fuel and vaporized oxidizer streams to form metal species-based nanoparticles in a flame that are deposited onto a temperature controlled support surface and sintered to form the metal species-based nanostructured film. Improved nanostructured photo-watersplitting cells having a sunlight to hydrogen conversion efficiency of from about 10% to about 15%, dye sensitized solar cells having a sunlight to electricity conversion efficiency of from about 10% to about 20%, and nanostructured p/n junction solar cells having a sunlight to electricity conversion of from about 10% to about 20% are provided. Each cell type comprises a nanostructured metal oxide film having continuous individual columnar structures having an average width (w) and grain size criterion (X | 12-09-2010 |
20100297722 | TRANSGENIC MOSS PRODUCING TERPENOIDS - The present invention generally relates to transgenic moss. One aspect of the invention provides a transgenic moss cell that produces or accumulates a terpenoid compound. Another aspect of the invention provides for methods of producing a terpenoid compound through culturing of the transgenic moss. | 11-25-2010 |
20100278751 | RADIOLABELED 2-AMINO-4-ALKYL-6-(HALOALKYL)PYRIDINE COMPOUNDS AND THEIR USE IN DIAGNOSTIC IMAGING - Radiolabeled 2-amino-4-alkyl-6-(haloalkyl)pyridine compounds are disclosed. In some aspects, the compounds bind to inducible nitric oxide synthase (iNOS) with high specificity. In some configurations, a compound comprising a radioisotope can be used for diagnostic imaging of iNOS distribution in a mammalian subject such as a human, using a scanning method such as positron emission tomography (PET scanning). Methods of synthesis of the compounds are also disclosed. | 11-04-2010 |
20100278732 | 1H-[1, 2, 3] TRIAZOLE SUBSTITUTED AMINO ACIDS AND USES THEREOF - Tracers for cationic amino acid transport systems and methods of synthesis are disclosed, including compounds comprising a 1H-[1,2,3]triazole moiety. Further disclosed are uses of the analogues, including in vivo imaging of tumors by Positron emission tomography (PET) or Single Photon Emission Computed Tomography (SPECT). | 11-04-2010 |
20100272702 | METHODS AND COMPOSITIONS FOR TREATING NEUROPATHIES - Methods of treating or preventing axonal degradation in neuropathic diseases in mammals are disclosed. The methods can comprise administering to the mammal an effective amount of an agent that acts by increasing sirtuin activity in diseased and/or injured neurons. The methods can also comprise administering to the mammal an effective amount of an agent that acts by increasing NAD activity in diseased and/or injured neurons. Also disclosed are methods of screening agents for treating a neuropathies and recombinant vectors for treating or preventing neuropathies. | 10-28-2010 |
20100261676 | Use of an Endogenous Ligand for Peroxisome Proliferator Activated Receptor Alpha to Treat Liver Disorders - Compositions comprising the peroxisome proliferator-activated receptor alpha (PPARα)-ligand 1-palmitoyl-2-oleoyl-sn-glycerol-3-phosphocholine (16:0/18:1-GPC) are disclosed. These compositions may be used for the prophylaxis and treatment of PPARα-related liver disorders including, but not necessarily limited to, fatty liver disease, to lower lipid and triglyceride levels, and to increase high density lipoprotein levels in animals. Foods modified with 1-palmitoyl-2-oleoyl-sn-glycerol-3-phosphocholine (16:0/18:1GPC) may be used to improve the metabolism of animals. | 10-14-2010 |
20100221748 | AMPK modulation as a method of regulating stem cell and cancer stem cell proliferation, self-renewal and differentiation - Methods are disclosed for decreasing stem cell proliferation, including cancer stem cell proliferation. These methods comprise administering to stem cells inhibitors of AMP activated protein kinase (AMPK). Methods for promoting stem cell growth by increasing stem cell proliferation, self-renewal and/or differentiation are also disclosed. These methods comprise administering AMPK activators to stem cells. Methods of achieving selective differentiation of stem cells are also disclosed. These methods comprise administering small molecules to stem cells that modulate AMPK activity. Applications of these methods are also disclosed, such as methods of increasing numbers of neuronal progenitor cells. These methods can be used therapeutically, such as for repair of spinal cord injuries, or for stimulating neurogenesis in the hippocampus, and other cell-based therapies. The methods can also be used for screening of compounds that can be activators or inhibitors of AMPK activity. | 09-02-2010 |
20100159594 | SINGLE CHAIN TRIMERS AND USES THEREFOR - Single chain trimer (SCT) molecules are disclosed, comprising an MHC antigen peptide sequence, a β | 06-24-2010 |
20100150836 | RADIOLABELLED BENZAMIDE ANALOGUES, THEIR SYNTHESIS AND USE IN DIAGNOSTIC IMAGING - Fluoroalkoxybenzamide compounds which selectively bind Sigma-2 receptors are disclosed. These compounds, when labelled with | 06-17-2010 |
20100121031 | MEMBRANE-PERMEANT PEPTIDE COMPLEXES FOR TREATMENT OF SEPSIS - Methods and compositions for treating sepsis and diseases and conditions involving cellular apoptosis using cell membrane-permeant peptide conjugates of a cell membrane permeant peptide together with anti-apoptotic domains of the TCL1 protein are provided. | 05-13-2010 |
20100120685 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER - Oligopeptides which can be used to treat cancer are disclosed. Further disclosed are methods of treating cancer, including breast cancer, skin cancer, prostate cancer and multiple myeloma (MM). These methods include administration of a polypeptide encoded by the Mesd gene, or an oligopeptide comprising a contiguous subsequence of a Mesd polypeptide. | 05-13-2010 |
20100114239 | METHODS FOR TREATING CENTRAL NERVOUS SYSTEM DAMAGE - Methods for the treatment of CNS damage are described, and include inducing in a subject in need of such treatment, a therapeutically effective amount of functional electronic stimulation (FES) sufficient to evoke patterned movement in the subject's muscles, the control of which has been affected by the CNS damage. The induction of FES-evoked patterned movement at least partially restores lost motor and sensory function, and stimulates regeneration of neural progenitor cells in the subject patient. | 05-06-2010 |
20100111944 | METHOD OF DIAGNOSING, CLASSIFYING AND TREATING ENDOMETRIAL CANCER AND PRECANCER - Diagnostic and therapeutic applications for endometrial cancer are described. The diagnostic and therapeutic applications are based on certain activation mutations in the FGFR2 gene and its expression products. The present invention is directed to nucleotide sequences, amino acid sequences, probes, and primers related to FGFR2 activation mutants and kits comprising these mutants to diagnosis and classify endometrial cancer in a subject. | 05-06-2010 |
20100094154 | METHOD FOR ANALYZING FUNCTION OF THE BRAIN AND OTHER COMPLEX SYSTEMS - A method and system are provided for analyzing electromagnetic brain signals such as EEG and ECoG signals in a subject in real time and which avoids the need for time-intensive retrospective analysis of brain activity in the subject. This can be applied to all complex systems with multiple fluctuating signals to identify and predict significant events | 04-15-2010 |
20100056609 | METHODS AND COMPOSITIONS FOR INHIBITION OF AXONAL DEGENERATION BY MODULATION OF THE DLK/JNK PATHWAY - Methods of reducing Wallerian degeneration are disclosed. These methods comprise inhibiting expression or activity of a mixed lineage kinas such as a dual leucine-zipper-bearing kinase (DLK), inhibiting expression or activity of a molecule acting downstream from DLK, such as a c-Jun N-terminal kinase (JNK), or a combination thereof. Further disclosed are methods of screening candidate compounds for DLK inhibition activity. These methods comprise providing a neuronal culture comprising a plurality of axons; contacting the culture with a candidate compound and with an axon degeneration-triggering agent; and comparing axonal degeneration in the culture to a control culture comprising the axon degeneration-triggering agent but not the candidate compound. | 03-04-2010 |
20100055712 | Oligopeptides for treatment of osteoporosis and other bone diseases and methods therefor - Methods of identifying compounds for treating Alzheimer's disease are disclosed. These methods comprise a) forming an in vitro mixture comprising i) cells expressing LDL receptor related protein 1 (LRP1), ii) an LRP1 ligand comprising a label, and iii) a candidate compound; and b) determining quantity of the label incorporated by the cells, whereby a candidate compound is deemed effective for treating Alzheimer's disease if the quantity of label incorporated by the cells exceeds that of a control in vitro mixture comprising cells expressing LRP1 and the LRP1 ligand, but not comprising the compound. | 03-04-2010 |
20100048614 | THERAPEUTIC USES OF BICYCLIC LIGANDS OF SIGMA 2 RECEPTOR - A series of N-substituted 9-azabicyclo[3.3.1]nonan-3α-yl phenylcarbamate analogs are disclosed, as well as methods of their preparation. Their affinities for sigma (σ1 and σ2) receptors are described. Two new compounds, N-(9-(4-aminobutyl)-9-azabicyclo[3.3.1]nonan-3α-yl)-N′-(2-methoxy-5-methylphenyl)carbamate and N-(9-(6-aminohexyl)-9-azabicyclo[3.3.1]nonan-3α-yl)-N′-(2-methoxy-5-methylphenyl)carbamate, are shown to have a high affinity and selectivity for σ2 versus σ1 receptors. Among the disclosed compounds are biotinylated and fluorescent analogs. These compounds can serve as probes to the σ2 receptor. In addition, some disclosed compounds can induce apoptotic cell death by both caspase-dependent and caspase-independent mechanisms, and are effective for treatment of tumors. The compounds can be used as chemotherapeutics or chemosensitizers in the treatment of a wide variety of solid tumors. | 02-25-2010 |
20100047177 | METHODS AND COMPOSITIONS FOR TREATING NEUROPATHIES - Methods of treating or preventing axonal degradation in neuropathic diseases and neurological disorders in mammals are disclosed. The methods can comprise administering to the mammal an effective amount of an agent that acts at least in part by increasing sirtuinAMPK activity, LKB 1 activity and/or CaMKKβ activity in diseased and/or injured neurons. The methods can also comprise administering to the mammal an effective amount of an agent that acts by increasing NAD activity in diseased and/or injured neurons, alone or in combination with agents that act by other mechanisms. Also disclosed are methods of screening agents for treating a neuropathies and recombinant vectors for treating or preventing such neuropathies. | 02-25-2010 |
20100040688 | HYDROGEL MICROPARTICLE FORMATION IN AQUEOUS SOLVENT FOR BIOMEDICAL APPLICATIONS - The field of the disclosure relates to microparticles comprising a cross-linked water-soluble polymer or cross-linked water-soluble polymers and a process for forming thereof. Further, the field of the disclosure relates to coatings and scaffolds comprising microparticles and the processes for forming thereof. | 02-18-2010 |
20100028936 | DETECTION OF CANCER CELLS IN VITRO USING SIGMA-2 RECEPTOR LIGANDS AS RADIOTRACERS - Methods for detection of cancer cells and for determining the proliferative status of cells in a tissue sample in vitro are disclosed. These methods comprise contacting a tissue sample with a radiolabeled compound or salt thereof of Formula | 02-04-2010 |
20100021381 | Natriuretic peptide-mediated imaging of atherosclerotic plaque - Tracers comprising an oligopeptide comprising a fragment of a natriuretic peptide, wherein the fragment comprises the sequence Arg-Ile-Asp-Arg-Ile (SEQ ID NO.: 1), and a signaling moiety, are disclosed. Further disclosed are methods of imaging atherosclerotic plaque by PET scanning or MRI using a tracer. | 01-28-2010 |
20100003264 | Reduction of Ophthalmalogic Neovascularization - The present invention generally relates to methods for treatment of neovascularization in various tissues of a patient's eye. One aspect of the invention is a method of treating a patient for ophthalmologic neovascularization by administering an anti-interleukin-10 agent to the eye of a patient in need thereof to decrease the amount of interleukin-10 in the eye. Another aspect of the invention is a method of treating a patient for ophthalmologic neovascularization by administering isolated macrophages to the eye of a patient in need thereof to decrease a volume of a neovascularization complex within the treated eye. | 01-07-2010 |
20090326337 | MULTIFUNCTIONAL NANOSCOPY FOR IMAGING CELLS - Disclosed herein is an apparatus for sensing characteristics of an object. In a preferred embodiment, the apparatus comprises an array, wherein the array comprises a plurality of nanoscale hybrid semiconductor/metal devices which are in proximity to an object, each hybrid semiconductor/metal device being configured to produce a voltage in response to a perturbation, wherein the produced voltage is indicative of a characteristic of the object. Any of a variety of nanoscale EXX sensors can be selected as the hybrid semiconductor/metal devices in the array. With such an array, ultra high resolution images of nanoscopic resolution can be generated of objects such as living cells, wherein the images are indicative of a variety of cell biologic processes. | 12-31-2009 |
20090299640 | Methods and Compositions Involving Intrinsic Genes - Disclosed are compositions and methods related intrinsic gene sets and methods and compositions related to detecting and classifying cancer. | 12-03-2009 |
20090269846 | Inhibitors of tyrosine kinase receptor dimerization - The teachings relate to methods of identifying inhibitors of dimerization of tyrosine receptor kinases such as EGFR. The methods comprise providing, on a digital computer, a molecular model comprising a complex of extracellular dimerization domains of an RTK, docking a chemical databases to the molecular model, scoring the compounds comprised by the database, and identifying one or more high-scoring compounds. The methods further comprise testing a compound for RTK inhibitory activity in vitro, and testing a compound for specificity as an RTK inhibitor. Also disclosed are compounds selected by the described methods, and methods of treatment using the compounds. Two compounds (NSC11241 and NSC56452) are disclosed that inhibit EGF receptor kinase activation in a dose-dependent manner. | 10-29-2009 |
20090263329 | CELL LABELING WITH PERFLUOROCARBON NANOPARTICLES FOR MAGNETIC RESONANCE IMAGING AND SPECTROSCOPY - Methods of obtaining cells internally labeled with perfluorocarbon nanoparticles suitable for magnetic resonance imaging and spectroscopy are disclosed. Also disclosed are methods for obtaining magnetic resonance imaging data from labeled under clinically relevant scan times and field strengths. Finally, the application further discloses methods of specifically detecting and distinguishing magnetic resonance imaging and spectroscopy data from two distinct sets of cells labeled with distinct types of perfluorocarbon nanoparticles. | 10-22-2009 |
20090258011 | Antibodies against west nile virus and therapeutic and prophylactic uses thereof - The present invention relates to compositions comprising antibodies or fragments thereof that immunospecifically bind to one or more antigens of a flavivirus, particularly of West Nile Virus (WNV), and methods for preventing, treating or ameliorating symptoms associated with a flavivirus, particularly of West Nile Virus (WNV), infection utilizing said compositions. In particular, the present invention relates to methods for preventing, treating or ameliorating symptoms associated with WNV infection, said methods comprising administering to a human subject an effective amount of one or more antibodies or fragments thereof that immunospecifically bind to a WNV antigen. The present invention also relates to detectable or diagnostic compositions comprising antibodies or fragments thereof that immunospecifically bind to a WNV antigen and methods for detecting or diagnosing WNV infection utilizing said compositions. | 10-15-2009 |
20090246803 | NAD BIOSYNTHESIS SYSTEMS - The present invention generally relates to a nicotinamide adenine dinucleotide (NAD) biosynthesis system and methods of screening for NAD biosynthesis effectors. Among the various aspects of the present invention is the provision of an in vitro-reconstituted mammalian NAD biosynthesis system that can be used for the high-throughput screening of chemical activators and inhibitors for mammalian NAD biosynthesis. Another aspect of the invention provides a method of identifying a compound that effects in vivo activity of NAD metabolic enzymes. Further aspects of the invention include nucleic acid sequences, vectors, and transformed cells that can be used in the methods described herein. | 10-01-2009 |
20090214436 | DICHROMIC FLUORESCENT COMPOUNDS - The present invention provides dichromic fluorescent compounds, as well as processes for making and methods for using the dichromic fluorescent compounds. | 08-27-2009 |
20090176705 | MODULAR PLATFORM FOR TARGETED THERAPEUTIC DELIVERY - Pharmaceutical compounds, pharmaceutical compositions and methods of treatment are disclosed, wherein a compound comprises a targeting moiety which, in free form, binds a cell receptor with a dissociation constant K | 07-09-2009 |
20090176207 | Methods for Determining Risk of Developing Regular Smoking Behavior - The present invention relates in general to human genetic polymorphisms and their association with human health and to methods and materials for analyzing allelic variations, and to the use of genetic polymorphisms in the diagnosis and treatment of smoking behavior and nicotine dependence. Provided herein are methods for determining risk in a subject of developing regular smoking behavior. Also provided are primers, probes, microarrays, and kits related thereto. | 07-09-2009 |
20090111172 | MURINE CALICIVIRUS - The invention disclosed herein relates to a newly discovered murine norovirus, and compositions and methods related thereto. | 04-30-2009 |
20090054951 | Electrode for Stimulating Bone Growth, Tissue Healing and/or Pain Control, and Method of Use - A screw for use in stimulating bone growth, tissue healing and/or pain control. The screw includes an elongate shaft having a length extending between opposite ends, an exterior surface and a screw thread formed on the exterior surface of the shaft and extending along at least a portion of the length. The shaft has an electrically conducting portion and an electrically insulating portion. The screw also includes a head adjacent one end of the shaft for engaging the screw to rotate the screw and thereby drive it into bone. The screw includes an electrical conductor electrically connectable to the shaft for conveying current through the shaft to the bone through the conducting portion of the shaft. | 02-26-2009 |
20080318202 | CHIMERIC PANCREAS - Novel methods, tissues and compositions for increasing the pancreatic mass of a mammalian recipient including harvesting immature pancreatic tissue from a mammalian donor and transplanting said tissue into the peritoneal cavity of a mammalian recipient under conditions that allow the pancreatic tissue to become vascularized and mature, thereby developing a functioning chimeric, endocrine pancreas that produces at least insulin in the recipient. The invention also includes mammalian immature pancreatic tissue adapted for transplantation into the peritoneal cavity of a mammalian recipient for increasing the pancreatic mass of the mammalian recipient as well as methods and compositions for treatment of the pancreatic tissue, recipient immunosuppression and recipient co-stimulatory blockade. | 12-25-2008 |
20080311644 | Amino Methylated 2-Pyridinones - Novel amino methylated 2-pyridinones, precursors, intermediates, and derivatives; the methods for the preparation of the same; uses of the same for inhibiting pili formation in bacteria; and pharmaceutical compositions comprising these compounds are described in this application. The present compounds may be employed to inhibit biofilm formation and thereby inhibit adherence of bacteria to a host cell. | 12-18-2008 |
20080226608 | Methods of Isolating and Using Enriched Subpopulations of Bone Marrow Progenitors for the Treatment of Diabetes - Enriched subpopulations of bone marrow progenitors are obtained according to methods that involve the staining of bone marrow cells and the identification of bone marrow progenitors within the stained cell population having specific intracellular fluorescence or orthogonal light scatter properties. Enriched subpopulations of the described progenitors may be used to lower blood glucose levels and treat hyperglycemia, and in particular hyperglycemia caused by Type 1 or Type 2 diabetes. | 09-18-2008 |
20080214670 | Therapeutic Malonic Acid/Acetic Acid C60 Tri-Adducts of Buckminsterfullerene and Methods Related Thereto - Disclosed and claimed herein are e,e,e malonic acid/acetic acid tri-adduct of buckminsterfullerene of the general formula C | 09-04-2008 |
20080213750 | HCV Variants and Related Methods - HCV variants are described. The variants include polynucleotides comprising non-naturally occurring HCV sequences and HCV variants that have a transfection efficiency and ability to survive subpassage greater than HCV that have wild-type polyprotein coding regions. Expression vectors comprising the above polynucleotides and HCV variants are also described, as are the provision of cells and host cells comprising the expression vectors. Methods for identifying a cell line that is permissive for infection with HCV are also provided, as are vaccines comprising the above polynucleotides in a pharmaceutically acceptable carrier. Additionally, methods for inducing immunoprotection to HCV in a primate are described, as are methods for testing a compound for inhibiting HCV replication. | 09-04-2008 |